>
Diagnos Inc logo

ADK - Diagnos Inc Share Price

C$0.47 -0.0  -4.1%

Last Trade - 2:41pm

Sector
Technology
Size
Micro Cap
Market Cap £19.0m
Enterprise Value £18.5m
Revenue £164k
Position in Universe 1360th / 2712
Bullish
Bearish
Unlock ADK Revenue
Momentum
Relative Strength (%)
1m -16.6%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -35.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.56 0.63 2.39 1.61 0.33 0.33 0.29 0.98 -10.1%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 31 December 2020, DiagnosInc revenues decreased 19% to C$205K. Net loss decreased33% to C$1.4M. Revenues reflect a decrease in demand forthe Company's products and services due to unfavorablemarket conditions. Lower net loss reflects Other incomeincrease from C$17K to C$259K (income), Interest expensedecrease of 85% to C$38K (expense), Loss on settlement ofdebt, including re decrease from C$176K (expense) to C$0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ADK Revenue Unlock ADK Revenue

Net Income

ADK Net Income Unlock ADK Revenue

Normalised EPS

ADK Normalised EPS Unlock ADK Revenue

PE Ratio Range

ADK PE Ratio Range Unlock ADK Revenue

Dividend Yield Range

ADK Dividend Yield Range Unlock ADK Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ADK EPS Forecasts Unlock ADK Revenue
Profile Summary

DIAGNOS Inc. provides data mining and interpretation consulting services, and designs data analytics software products. The Company operates through two segments: Healthcare and Natural resources. Its Healthcare segment offers image analysis services through Computer Assisted Retinal Analysis (CARA), a software tool, which assists health specialists in the detection of diabetic retinopathy. CARA is a hosted Web-based application that integrates fundus cameras with an image processing engine over an Internet connection. Its Natural resources segment offers data mining consulting services through Computer Aided Resource Detection System (CARDS), a software tool used to assist exploration companies in identifying mining deposits. In addition, it offers project management services. The Company operates in Canada, the United Arab Emirates, India, Mexico, Switzerland, the United States, Poland and Colombia.

Directors
Last Annual March 31st, 2020
Last Interim December 31st, 2020
Incorporated April 11, 1996
Public Since November 19, 1990
No. of Shareholders: n/a
No. of Employees: n/a
Sector Technology
Industry Software & IT Services
Index
Exchange TSX Venture Exchange
Shares in Issue 65,625,925
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ADK Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ADK
Upcoming Events for ADK
Frequently Asked Questions for Diagnos Inc
What is the Diagnos Inc share price?

As of 2:41pm, shares in Diagnos Inc are trading at C$0.47, giving the company a market capitalisation of £19.0m. This share price information is delayed by 15 minutes.

How has the Diagnos Inc share price performed this year?

Shares in Diagnos Inc are currently trading at C$0.47 and the price has moved by 0.158k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Diagnos Inc price has moved by 91.51% over the past year.

What are the analyst and broker recommendations for Diagnos Inc?

Of the analysts with advisory recommendations for Diagnos Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Diagnos Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Diagnos Inc next release its financial results?

Diagnos Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Diagnos Inc dividend yield?

Diagnos Inc does not currently pay a dividend.

Does Diagnos Inc pay a dividend?

Diagnos Inc does not currently pay a dividend.

When does Diagnos Inc next pay dividends?

Diagnos Inc does not currently pay a dividend.

How do I buy Diagnos Inc shares?

To buy shares in Diagnos Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Diagnos Inc?

Shares in Diagnos Inc are currently trading at C$0.47, giving the company a market capitalisation of £19.0m.

Where are Diagnos Inc shares listed? Where are Diagnos Inc shares listed?

Here are the trading details for Diagnos Inc:

Country of listing: Canada
Exchange: CVE
Ticker Symbol: ADK
What kind of share is Diagnos Inc?

Based on an overall assessment of its quality, value and momentum, Diagnos Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Diagnos Inc share price forecast 2021?

Shares in Diagnos Inc are currently priced at C$0.47. At that level they are trading at 70% discount to the analyst consensus target price of 0.00.

Analysts covering Diagnos Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.03 for the next financial year.

How can I tell whether the Diagnos Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Diagnos Inc. Over the past six months, the relative strength of its shares against the market has been -27.67%. At the current price of C$0.47, shares in Diagnos Inc are trading at 14.23% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Diagnos Inc PE Ratio?

We were not able to find PE ratio data for Diagnos Inc.

Who are the key directors of Diagnos Inc?

Diagnos Inc's management team is headed by:

Andre Larente - PRE
Marc-andre Massue - CFO
Georges Hebert - IND
Reid Maclellan - IND
Riadh Kobbi - VPR
Francis Bellido - IND
Who are the major shareholders of Diagnos Inc?

Here are the top five shareholders of Diagnos Inc based on the size of their shareholding:

Coffin (Tristram Robert) Individual Investor
Percentage owned: 16.88% (11.1m shares)
9071-8776 Quebec, Inc Corporation
Percentage owned: 11.86% (7.78m shares)
Dunn (Robert) Individual Investor
Percentage owned: 2.33% (1.53m shares)
Hebert (Georges Lawrence) Individual Investor
Percentage owned: 2.17% (1.42m shares)
Palos Management Inc. Investment Advisor
Percentage owned: 0.91% (600k shares)
Similar to ADK
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.